Financials
Financial year 2025
CD3 Labs from Leuven, company number BE0888594828, closed financial year 2025 with a result of € -118,898 after tax. For that financial year CD3 Labs recorded revenue of € 10 million and equity of € 21,267. Compared with financial year 2024, the result moved from € 98,510 to € -118,898. The company made a loss. The buffer shrank hard: equity is 85 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.
€ 21,267
▼ 85% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -118,898
▼ still € 98,510 profit in 2024
Profit after tax over the fiscal year.
€ 286,100
▼ 47% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
43.5
▲ 0.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 6 million
▲ 15% vs 2024
€ 137,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 858,695
▲ 54% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 904,045
▼ 3% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 9,693,178 | € 10,640,413 | € 11,076,821 | € 9,997,131 | ▼ 10% |
| Gross margin | € 4,532,292 | € 5,000,925 | € 5,341,072 | € 5,851,148 | ▲ 10% |
| Profit after taxes | € -107,192 | € 16,950 | € 98,510 | € -118,898 | ▼ € 217,408 |
| Equity | € 24,705 | € 41,655 | € 140,165 | € 21,267 | ▼ 85% |
| Total debts | € 1,719,958 | € 1,648,327 | € 1,490,791 | € 1,765,457 | ▲ 18% |
| Cash | € 113,169 | € 345,847 | € 536,954 | € 286,100 | ▼ 47% |
| Land & buildings | € 135,553 | € 114,399 | € 93,620 | € 72,841 | ▼ 22% |
| Retained profit | € 24,705 | € 41,655 | € 140,165 | € 21,267 | ▼ 85% |
| Balance sheet total | € 1,744,664 | € 1,689,982 | € 1,630,956 | € 1,786,723 | ▲ 10% |
| Employees (FTE) | 38.8 | 43 | 42.7 | 43.5 | ▲ 0.8 |
Key figures of CD3 Labs, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CD3 Labs?
What happened at CD3 Labs in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 118,898 (▼ € 217,408 vs 2024). Source: NBB ↗
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 107,192 loss in 2022 to € 118,898 loss in 2025.
Paid € 5,918 in corporate taxes since 2022.
Best year ever: 2024, with € 98,510 profit.
On average € 134,500 of value added per employee in 2025.
A new publication or filing at CD3 Labs? We notify you, reason included.
Follow CD3 LabsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind CD3 Labs are Paul Van Dun , Patrick Chaltin and Yves Vertenten. Paul Van Dun is also behind Regionaal Ziekenhuis Heilig Hart Tienen, reMYND, VersaSense, Zeopore Technologies and Wetenschapspark Leuven Noord.
Directors
According to the 2025 annual accounts
Paul Van Dun
Director
Also active at: Regionaal Ziekenhuis Heilig Hart Tienen, reMYND, VersaSense, Zeopore Technologies, Wetenschapspark Leuven Noord, PARKEERGEBOUW, Community Building Arenberg
Patrick Chaltin
Director
Yves Vertenten
Director
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 2
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
BELNET, BE
Website info
Features
Security
Network
Details
- Company number
- 0888.594.828
- VAT number
- BE 0888.594.828
- Registered office
- Gaston Geenslaan 2, 3001 Leuven
- Names & denominations
- CD3 Labs
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 30 March 2007
- Peppol
- Active · Active since 4 Dec 2025
- Contact
- cistim.be
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied